Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma

Puja Aggarwal, Robert Bone, Blaise Nwotchouang, Nicholas Moffett, Solly Chedid, Muhamed Baljevic, Bruce Feinberg

Blood (2025) 146 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2025-4572

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Advancing adoption of evidence-based quadruplet treatment regimens for newly diagnosed multiple myeloma in community practice: Insights from a quality improvement initiative

Nisha Joseph, Muhamed Baljevic, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Shelby Sullivan

Blood (2025) 146 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2025-2625

Published: 2025

Journal Articles

Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM)

Nicholas Moffett, Muhamed Baljevic, Robert Bone, Blaise Nwotchouang, Bruce Feinberg

Blood (2025) 146 (Supplement 1): 8125.

https://doi.org/10.1182/blood-2025-8125

Published: 2025

Journal Articles

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial

Puja Aggarwal, Robert Bone, Blaise Nwotchouang, Nicholas Moffett, Luke Jennings-Zhang, Solly Chedid, Muhamed Baljevic, Bruce Feinberg

Blood (2025) 146 (Supplement 1): 7938.

https://doi.org/10.1182/blood-2025-7938

Published: 2025

Journal Articles

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Nadine Abdallah, Jay R. Hydren, Mason S. Barnes, Andrew Wood, Sascha Alexander Tuchman, Jeffrey A. Zonder, Giada Bianchi, Heather J. Landau, Muhamed Baljevic, James E. Hoffman, Ana M. Sahagun Sanchez Aldana, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 5143.

https://doi.org/10.1182/blood-2024-208737

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Muhamed Baljevic, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie Callander, Noa Biran, Dane Van Domelen, Tomer Mark, Darrell White

Blood (2024) 144 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2024-208086

Published: 2024

Journal Articles

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fan Wang, Heiko Babel, Vanessa Schmitt, Muhammad Erfan Uddin, Muhamed Baljevic, Peter M. Voorhees, Cesar Rodriguez, Shaji Kumar, Hira Mian, Anders Erik Svensson, Chetasi Talati, Sven Mensing, Rajeev M Menon, Benjamin Engelhardt, Akshanth R Polepally

Blood (2024) 144 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2024-206054

Published: 2024

Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2024-206912

Published: 2024

Journal Articles

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Sarah Tjards, Robin High, Matthew A Lunning, Tanya M. Wildes, Julie M. Vose, Muhamed Baljevic, Sarah A. Holstein, Christopher R D'Angelo

Blood (2023) 142 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2023-179971

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2023-190746

Published: 2023

Journal Articles

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Blood (2023) 142 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2023-189808

Published: 2023

Journal Articles

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Gary J. Schiller, Sascha A. Tuchman, Natalie Callander, Muhamed Baljevic, Adrianna C Rossi, Rami Kotb, Darrell J White, Nizar J. Bahlis, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Christopher P. Venner, William I. Bensinger, Dane R. Van Domelen, Chris Zhang, Ohad S. Bentur, Brea Lipe

Blood (2022) 140 (Supplement 1): 10050–10053.

https://doi.org/10.1182/blood-2022-158011

Published: 2022

Journal Articles

The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Brooke Dulka, Robert N. Bone, Yolaine Jeune-Smith, Muhamed Baljevic, Bruce A. Feinberg

Blood (2022) 140 (Supplement 1): 10958–10959.

https://doi.org/10.1182/blood-2022-166490

Published: 2022

Journal Articles

Provider Perceptions of Shine and Ibrutinib, Bendamustine, and Rituximab in the First-Line Setting

Samuel C. Baird, Robert N. Bone, Yolaine Jeune-Smith, Bruce A. Feinberg, Muhamed Baljevic

Blood (2022) 140 (Supplement 1): 13234–13235.

https://doi.org/10.1182/blood-2022-166976

Published: 2022

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Advancing adoption of evidence-based quadruplet treatment regimens for newly diagnosed multiple myeloma in community practice: Insights from a quality improvement initiative

Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM)

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial

AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Provider Perceptions of Shine and Ibrutinib, Bendamustine, and Rituximab in the First-Line Setting

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only